We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

ChemDiv and Berlex Announce Collaboration

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

ChemDiv, Inc. has announced that it has entered into a discovery research collaboration with Berlex Inc., a U.S. affiliate of Schering AG, Germany. The partners will work on the discovery of potential new lead compounds against several selected GPCR targets.

Under the terms of the collaboration, ChemDiv will apply its integrated synthetic and medicinal chemistry capabilities and collaborate with Berlex's scientists in the search for new disease therapies.

"We are looking forward to the opportunity to work with Berlex and view this as further validation of our discovery chemistry expertise," said Alexander Kiselyov, Executive VP of R&D at ChemDiv, Inc.

"ChemDiv's integrated drug discovery capabilities provide an excellent fit for Berlex and we hope that our collaborative relationship will be a long-standing one."